Sterling Capital Management LLC Has $14.85 Million Stake in Amgen Inc. $AMGN

Posted by George Bondi on Jun 27th, 2026

Sterling Capital Management LLC raised its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 5.1% during the first quarter, HoldingsChannel.com reports. The fund owned 42,218 shares of the medical research company’s stock after buying an additional 2,060 shares during the quarter. Sterling Capital Management LLC’s holdings in Amgen were worth $14,854,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after purchasing an additional 961,975 shares during the period. State Street Corp grew its stake in Amgen by 4.4% during the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after purchasing an additional 1,287,310 shares during the period. Capital World Investors grew its stake in Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares during the period. Capital International Investors increased its holdings in Amgen by 1.5% in the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after purchasing an additional 282,219 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after purchasing an additional 1,035,779 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Up 1.6%

NASDAQ AMGN opened at $358.61 on Friday. The company has a market cap of $193.54 billion, a price-to-earnings ratio of 24.96, a P/E/G ratio of 3.54 and a beta of 0.42. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $391.29. The business has a 50 day moving average price of $340.70 and a 200-day moving average price of $346.20. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN – Get Free Report) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same period in the prior year, the firm earned $4.90 earnings per share. Amgen’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts expect that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of research analyst reports. Morgan Stanley increased their price target on Amgen from $332.00 to $340.00 and gave the stock an “equal weight” rating in a report on Tuesday, June 9th. Guggenheim dropped their target price on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a research report on Monday, May 4th. Cantor Fitzgerald reissued a “neutral” rating and set a $350.00 target price on shares of Amgen in a research note on Wednesday, April 8th. Argus reduced their price target on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a report on Wednesday, May 20th. Finally, Jefferies Financial Group began coverage on shares of Amgen in a research note on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $354.42.

View Our Latest Research Report on AMGN

Amgen Company Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.